NSW researchers in depression gene find
17 January, 2006 by Graeme O'NeillWinston Churchill called it his 'black dog'. Abraham Lincoln suffered from bipolar disorder, as did German composer Robert Schumann, and Dutch artist Vincent van Gogh. And a slew of poets including Alfred Lord Tennyson, William Blake, Edgar Allan Poe, Lord Byron and Sylvia Plath lived with manic depression.
Proteome Systems touts Huntington's biomarker find
13 January, 2006 by Ruth BeranSix months from completing an 18-month collaboration with the US-based High Q Foundation, Sydney's Proteome Systems (ASX:PXL) has statistically validated some of the multiple biomarkers for the inherited neurodegenerative disorder Huntington's disease which it identified in an earlier smaller study.
Starpharma HIV drug gets on FDA fast track
09 January, 2006 by Ruth BeranThe US Food and Drug Administration (FDA) has granted 'fast track' status to Melbourne drug developer Starpharma's (ASX:SPL) VivaGel.
Enlisting microbicides in the fight against HIV/AIDS
16 December, 2005 by Sir Gustav NossalSir Gustav Nossal writes that Australian scientists are at the vanguard of developing what could be the most effective weapons in the battle against one of the deadliest of diseases.
Medical Therapies sets out skin cancer animal trial plan
15 December, 2005 by Helen SchullerNewly-listed firm Medical Therapies (ASX:MTY) is set to begin a large-scale mouse study examining the effectiveness of its topical cream therapies as preventatives and cures for a variety of skin cancers.
GroPep changes track from psoriasis drug to asthma
14 December, 2005 by Ruth BeranFollowing poor efficacy in preclinical testing of its T-cell peptide drug candidate in psoriasis models, Adelaide biopharma GroPep (ASX:GRO) will undertake a market feasibility assessment for use of the drug in asthma.
Dia-B shares soar after filing insulin patent
08 December, 2005 by Ruth BeranDiabetes specialist Dia-B Tech's (ASX:DIA) shares rose nearly 70 per cent yesterday on news that it had filed a new Australian provisional patent to protect a mechanism for dispersing insulin more rapidly.
Why we should worry about zoonoses
02 December, 2005 by Graeme O'NeillZoonoses are a growing global problem requiring a global surveillance and control system, reports Graeme O'Neill.
'Perfect mismatch' heralds revolution in transplant technology
02 December, 2005 by Graeme O'NeillDelegates to an international tissue-typing workshop in Melbourne this week were told of a remarkable discovery by the University of Perugia immunogeneticist that is beginning to revolutionise tissue- and organ transplantation -- and cure leukaemia.
Novogen launches phase II therapy trial
01 December, 2005 by Graeme O'NeillMarshall Edwards, the US-based subsidiary of Australian cancer drug developer Novogen (ASX:NRT, NASDAQ:NVGN), has begun a phase Ib/IIa trial of Novogen's investigational chemotherapy re-sensitising drug phenoxodiol.
Biotech for the rest of the world
23 November, 2005 by Susan WilliamsonThe latest medical technology is all very well - if you can afford it. Susan Williamson looks at how one Australian group is coming up with practical healthcare solutions for the developing world.
Cancer breakthrough for UQ researchers
16 November, 2005 by Graeme O'NeillUniversity of Queensland researchers have reported spectacular success in killing cervical cancer cells and preventing the cancer in female mice, using RNA-interference (RNAi) therapy.
Rockeby shares soar after bird flu test deal
08 November, 2005 by Ruth BeranShares in Rockeby Biomed (ASX:RBY) quadrupled in value today after the company announced it has signed a deal with Thailand-based Pacific Biotech for the exclusive marketing and distribution rights in Europe, the Asia-Pacific and South Africa to two tests for avian flu.
Prana pleased with Alzheimer's trial results
07 November, 2005 by Graeme O'NeillPrana Biotech (ASX:PBT, NASDAQ:PRAN) announced today that its candidate PBT2 therapy for Alzheimer's disease has come through a phase I single-dose escalation trial in the Netherlands, with a superior pharmacokinetic profile to its predecessor, clioquinol.
Resonance expands into liver fibrosis
04 November, 2005 by Helen SchullerPerth-based Resonance Health Group (ASX:RHT) will progress to being a "two-product company" with the commercialisation of a new test for liver fibrosis, the company's managing director said this week.
